<DOC>
	<DOCNO>NCT02251795</DOCNO>
	<brief_summary>Study determine effect steady-state plasma concentration Tipranavir/ritonavir ( TPV/r ) platelet aggregation healthy subject investigate effect TPV/r steady state plasma concentration platelet function biomarkers coagulation fibrinolysis .</brief_summary>
	<brief_title>Effects Steady State Tipranavir/Ritonavir Darunavir/Ritonavir Ritonavir Platelet Function , Coagulation Fibrinolysis Biomarkers Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>1 . Ability willingness give write informed consent participate study ( i.e. , prior studyspecific procedure ) 2 . Age ≥18 year ≤50 year 3 . Female subject childbearing potential eligible : They use barrier contraceptive method least 12 week administration study medication negative serum pregnancy test result screen period ( Day 35 Day 3 ) ; , Were abstinent 12 week screen negative serum pregnancy test result screen period ( Day 35 Day 3 ) ; , Had document tubal ligation negative serum pregnancy test result screen period ( Day 35 Day 3 ) 4 . Ability swallow capsule without difficulty 5 . Reasonable probability complete study 6 . Findings medical history , physical examination 12lead ECG indicate subject healthy suitable trial opinion investigator 7 . Agreement abstain alcohol consumption drug abuse study 8 . Agreement abstain ingestion grapefruit , grapefruit juice , Seville oranges , orange marmalade screen period end study 9 . Negative urine drug screen drug abuse 10 . Non smoker 11 . Agreement abstain use tobacco product screen period end study 12 . Negative HIV1 serology ELISA test 13 . Negative Hepatitis B surface Antigen test ( HBsAg ) 14 . Negative Hepatitis C Virus antibody ( antiHCV ) test Enzyme Immunoassay 15 . Platelet count ≥125,000/mm3 16 . Hemoglobin ≥11.0 g/dL 17 . Prothrombin time ≤1.0 x upper limit normal ( ULN ) 18 . Activated Partial thromboplastin time ≤1.0 x ULN 1 . Female subject : positive serum pregnancy test screening period ( Day 35 Day 3 ) study breast feed plan breast feed time screen period 30 day last dose study drug willing use barrier method contraception time screen period 30 day last dose study drug take hormonal therapy reason birth control replacement therapy 2 . Had use investigational agent within 30 day prior Visit 2 3 . Blood plasma donation ( &gt; 100 mL total ) research altruistic reason within 30 day prior Visit 2 4 . Had use aspirin nonsteroidal antiinflammatory agent ( NSAID ) , include COX2 inhibitor , dipyridamole , clopidogrel , ticlopidine antiplatelet drug within 14 day prior Visit 2 study 5 . Active peptic ulceration history peptic ulcer disease 6 . Known history suspect hypersensitivity aspirin , NSAID component test drug ( Tipranavir , Darunavir , Ritonavir ) 7 . Known hypersensitivity antiretroviral drug ( market experimental drug clinical research study ) 8 . Active bleed disorder history active bleeding disorder 9 . Active Intra cranial hemorrhage ( ICH ) history ICH 10 . Active coronary artery disease history coronary artery disease 11 . Alcohol abuse ( 60 g/day ) 12 . Any indication current use aspirin NSAID indication use Visit 2 Visit 18 13 . Had use overthecounter medication within 7 day prior Visit 2 , current use prescription drug 14 . Subjects abnormal laboratory result Grade 1 great , defined Division AIDS Table Grading Severity Adult Pediatric Adverse Events ( DAIDS ) , ( result must available least 3 day prior Visit 2Day 1 ) , except follow screen laboratory value : serum potassium , serum sodium , serum phosphate uric acid , central laboratory reference range use determine eligibility rather DAIDS table ; , amylase creatinine result Grade 1 DAIDS table result consider clinically significant investigator ; marginally abnormal laboratory value consider clinically significant investigator approve clinical monitor 15 . History illness opinion investigator might confound result study pose additional risk administer aspirin , Tipranavir , Darunavir , Ritonavir 16 . Hypersensitivity sulphonamide drug 17 . Had use proton pump inhibitor 14 day prior Visit 2 18 . Vitamin E intake excess 60 mg/day within 30 day prior Visit 2 19 . Vitamin E supplementation excess 60 mg/day study ( Vitamin E content multivitamin tablet allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>